PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New evidence reveals tamoxifen reduces breast cancer rates by nearly a third for 20 years

2014-12-11
(Press-News.org) The preventive effect of breast cancer drug 'tamoxifen' remains virtually constant for at least 20 years - with rates reduced by around 30 per cent - new analysis published in The Lancet Oncology reveals.

The IBIS-I trial (International Breast Cancer Intervention Study), led by Queen Mary University of London and funded by Cancer Research UK, examined the long-term risks and benefits of taking tamoxifen to prevent breast cancer in women at high risk of the disease (aged 35-70 years old, primarily with a family history of breast cancer).

During the study* 7,154 pre and post-menopausal women were randomised to receive either tamoxifen (20mg daily) or a matching placebo for five years. After completing treatment, the health of all participants was monitored with an average follow-up time of 16 years and maximum of 22 years.

The new and extended analysis, presented at the San Antonio Breast Cancer Symposium, revealed 251 women from the tamoxifen group versus 350 from the placebo group developed breast cancer - a reduction of 29 per cent. Oestrogen receptor (ER) positive invasive cancer (accounting for two thirds of all breast cancers**) was reduced by 35 per cent.

After 20 years of follow up, the estimated risk of developing breast cancer was 8 per cent in the tamoxifen group, compared to 12 per cent in the placebo group. This equates to 22 women being treated with tamoxifen for every one breast cancer case prevented after 20 years.

Professor Jack Cuzick, Lead Author and Head of the Centre for Cancer Prevention at Queen Mary University of London, comments: "Tamoxifen is a well-established and effective treatment for certain breast cancers, but we now have evidence of its very long-term preventive benefits. The preventive effect of tamoxifen is highly significant with a reduction in breast cancer rates of around a third, and this impact has remained strong and unabated for 20 years. We hope these results will stimulate more women, particularly younger women, to consider treatment options for breast cancer prevention if they have a family history of the disease or other major risk factors."

Women who took hormone replacement therapy during the five years of tamoxifen treatment had a significantly lower benefit compared with those who did not. In addition, endometrial cancer - a known side effect of tamoxifen - was 3.8 times more common in the tamoxifen group during the five years of treatment (15 tamoxifen versus 4 placebo), but there was no increased risk in the follow-up period. Overall, nine extra cases were seen in the tamoxifen arm (29 tamoxifen versus 20 placebo).

A reduction in breast cancer specific deaths following tamoxifen treatment has not yet been seen (31 tamoxifen versus 26 placebo). In addition, five women receiving tamoxifen died from endometrial cancer compared to none in the placebo group. Deaths from other causes were very similar in both groups (146 tamoxifen versus 140 placebo).

Professor Jack Cuzick continues: "Despite a clear and continuing reduction in breast cancer rates, this has not yet resulted in a reduction in breast cancer deaths. However, the number of deaths is still small compared with the number of breast cancer cases - which is 10 times higher. We will need to continue monitoring these women for a further decade to get a clearer picture of the impact of tamoxifen on death rates. Some of the side effects of tamoxifen are also cause for concern and need continued monitoring - specifically the increased occurrence of endometrial cancer."

The extended analysis of the IBIS-I trial is announced a year after the first results of the IBIS-II trial were released, which found taking the breast cancer drug anastrozole (an aromatase inhibitor) for five years reduced the chances of post-menopausal, high risk women developing the disease by 53 per cent compared with women who took a placebo.

Professor Cuzick concludes: "Breast cancer prevention has come a long way, with many more options now available to women at high risk of the disease. For most post-menopausal women, we believe another type of drug - an aromatase inhibitor, such as anastrozole - should be the drug of choice, as they are more effective than tamoxifen and have fewer side effects. Following our calls for NICE to include anastrozole in their clinical guidelines for breast cancer prevention, this is currently under consideration.

"However, for most premenopausal, high risk women, tamoxifen remains the only drug choice for breast cancer prevention and it is a good one - as shown by this new evidence.

"A healthy diet and increased physical activity can help to prevent breast cancer, but for high risk women a more powerful intervention is needed. This is where tamoxifen, which is already recommended by NICE, and anastrozole which we hope will one day be available, have a role to play."

Dr Julie Sharp, Head of Health Information at Cancer Research UK, said: "The landmark IBIS trials show the value of chemoprevention for women at high risk of breast cancer and highlight just how important these large and long-term studies are. This follow up of IBIS-I confirms that tamoxifen has a long-lasting effect in reducing cases of breast cancer in women at high risk of the disease. All these drugs have side effects so it's important that women at high risk of breast cancer talk through their choices with their doctor to work out the best option for them."

INFORMATION:

For more information contact: Charli Scouller
PR Manager
Queen Mary University of London
c.scouller@qmul.ac.uk
Tel: 020 7882 7943 / 07709 825 741

Notes to the editor

* The first results of the IBIS-I trial were published in 2002. A synopsis can be found here: http://www.ncbi.nlm.nih.gov/pubmed/12243915

** Figure taken from CR-UK website: http://www.cancerresearchuk.org/about-cancer/type/breast-cancer/treatment/which-treatment-for-breast-cancer#erstatus

Interview requests: Professor Jack Cuzick and the IBIS-I team will be in San Antonio, Texas, presenting these findings at the San Antonio Breast Cancer Symposium. If you would like to speak to Professor Cuzick or request an interview, please get in touch with Charli Scouller (contact details above) and this can be arranged via phone or Skype, or questions can also be answered on email. Clinicians involved in the study are available in the UK for broadcast interviews, and patient case studies are available upon request.

About Queen Mary University of London Queen Mary University of London is among the UK's leading research-intensive higher education institutions, with five campuses in the capital: Mile End, Whitechapel, Charterhouse Square, West Smithfield and Lincoln's Inn Fields.

A member of the Russell Group, Queen Mary is also one of the largest of the colleges of the University of London, with 17,800 students - 20 per cent of whom are from more than 150 countries.

Some 4,000 staff deliver world-class degrees and research across 21 departments, within three Faculties: Science and Engineering; Humanities and Social Sciences; and the School of Medicine and Dentistry.

Queen Mary has an annual turnover of £350m, research income worth £100m, and generates employment and output worth £700m to the UK economy each year.

Unique for London universities, Queen Mary has an integrated residential campus in Mile End - a 2,000-bed award-winning Student Village overlooking the scenic Regents Canal.

About Cancer Research UK

Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research The charity's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated. Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years. Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses. Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.

For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.cancerresearchuk.org. Follow us on Twitter and Facebook.



ELSE PRESS RELEASES FROM THIS DATE:

Water's role in the rise and fall of the Roman Empire

Waters role in the rise and fall of the Roman Empire
2014-12-11
Smart agricultural practices and an extensive grain-trade network enabled the Romans to thrive in the water-limited environment of the Mediterranean, a new study shows. But the stable food supply brought about by these measures promoted population growth and urbanisation, pushing the Empire closer to the limits of its food resources. The research, by an international team of hydrologists and Roman historians, is published today in Hydrology and Earth System Sciences, an open access journal of the European Geosciences Union (EGU). Stretching over three continents and persisting ...

Early identification of modifiable risk factors for cognitive decline

2014-12-11
Phoenix, AZ (December 11th, 2014) - Signs of cognitive decline related to aging populations, and even the severe cognitive losses seen in Alzheimer's disease and neurodegenerative disorders, may emerge many years earlier, according to a report presented today at the American College of Neuropsychopharmacology annual meeting in Phoenix (Arizona). The study suggests that early signs of cognitive decline are already present for some individuals during midlife, and that they are linked with risk factors such as elevated blood pressure. It is possible that if these risk factors ...

Short sleep duration and sleep-related breathing problems increase obesity risk in kids

2014-12-11
December 11, 2014--(BRONX, NY)--Sleep-related breathing problems and chronic lack of sleep may each double the risk of a child becoming obese by age 15, according to new research from Albert Einstein College of Medicine of Yeshiva University. The good news is that both sleep problems can be corrected. The study, which followed nearly 2,000 children for 15 years, published online today in The Journal of Pediatrics. "In recent years, lack of sleep has become a well-recognized risk for childhood obesity," said Karen Bonuck, Ph.D., professor of family and social medicine ...

Human exposure to metal cadmium may accelerate cellular aging

2014-12-11
WASHINGTON, DC (December 11, 2014)--A new study led by a researcher at Milken Institute School of Public Health (Milken Institute SPH) at the George Washington University looks at the metal cadmium and finds that higher human exposure can lead to significantly shorter telomeres, bits of DNA at the ends of chromosomes that are associated with cardiovascular disease, diabetes and other diseases of old age. The study, which was published online today in the American Journal of Epidemiology, is the largest-ever to look at cadmium exposure and telomeres. "We looked at heavy ...

One in 6 Ontario adults say they've had a traumatic brain injury in their lifetime

2014-12-11
TORONTO, Dec. 11, 2014 -- Nearly seventeen per cent of adults surveyed in Ontario said they have suffered a traumatic brain injury that left them unconscious for five minutes or required them to be hospitalized overnight, according to new research. These same adults also reported more substance use, smoking and recent psychiatric distress. Researchers compared the prevalence of reported TBI with current substance use, cigarette smoking and psychological distress among 1,999 Ontario adults. "We found that one in six Ontario adults reported a history of TBI," said Dr. ...

Nighttime gout attack risk more than 2 times higher than in the daytime

2014-12-11
Novel research reveals that the risk of acute gout attacks is more than two times higher during the night or early morning hours than it is in the daytime. The study published in Arthritis & Rheumatology, a journal of the American College of Rheumatology (ACR), confirms that nocturnal attacks persist even among those who did not consume alcohol and had a low amount of purine intake during the 24 hours prior to the gout attack. The body produces uric acid from the process of breaking down purines--natural substances in cells in the body and in most foods--with especially ...

Higher rate of asthma seen in toddlers who share a bed with their parents

2014-12-11
New research suggests that toddlers who share a bed with their parents might have an increased risk of asthma in later childhood. The study, which is published online today (11 December, 2014) in the European Respiratory Journal, sheds light on the potential health effects of bed-sharing for infants and toddlers. The researchers investigated 6,160 mothers and their children in Rotterdam, the Netherlands. They collected information via a questionnaire on wheezing and asthma symptoms every year from the age of one to six years. They also assessed sleeping patterns at ...

New study into life-threatening pregnancy condition calls for specialist centers

2014-12-11
A new study has revealed key steps for hospitals to improve care for pregnant mums and babies affected by a life-threatening condition. In the UK today, almost one in every 100 babies is stillborn or dies soon after birth. Up to 100 women die every year during or just after pregnancy. A team of academics, clinicians and charity representatives, called MBRRACE-UK*, has looked at how care for mothers and babies can be improved. The report, commissioned by the Healthcare Quality Improvement Partnership as part of the Clinical Outcome Review Programmes**, is led by a team ...

Boosting chemical by-product of dietary fiber fermentation in gut slims and trims

2014-12-11
This approach may offer a new weight management option, suggest the researchers. Animal studies have shown that the natural fermentation of dietary fibre by gut bacteria produces short chain fatty acids, one of which is propionate. These fatty acids stimulate the release of the gut hormones PYY and GLP-1, which in turn suppress appetite. And propionate seems to be the most effective at stimulating PYY and GLP-1 release. To find out if increasing levels of propionate in the bowel could reduce food intake and stave off weight gain in people, the researchers developed ...

Added sugars likely to have greater role than salt in high blood pressure and heart disease

2014-12-11
Dietary guidelines should emphasise the role played by added sugars, particularly fructose, in the fight to curb the prevalence of cardiovascular, they insist. Cardiovascular disease is the number one cause of premature death in the developed world. And high blood pressure is its most important risk factor,accounting for almost 350,000 deaths in the US in 2009 and costing more than $50 billion US dollars every year. Dietary approaches to lower high blood pressure have historically focused on cutting salt intake. But the potential benefits of this approach "are debatable," ...

LAST 30 PRESS RELEASES:

New tablet shows promise for the control and elimination of intestinal worms

Project to redesign clinical trials for neurologic conditions for underserved populations funded with $2.9M grant to UTHealth Houston

Depression – discovering faster which treatment will work best for which individual

Breakthrough study reveals unexpected cause of winter ozone pollution

nTIDE January 2025 Jobs Report: Encouraging signs in disability employment: A slow but positive trajectory

Generative AI: Uncovering its environmental and social costs

Lower access to air conditioning may increase need for emergency care for wildfire smoke exposure

Dangerous bacterial biofilms have a natural enemy

Food study launched examining bone health of women 60 years and older

CDC awards $1.25M to engineers retooling mine production and safety

Using AI to uncover hospital patients’ long COVID care needs

$1.9M NIH grant will allow researchers to explore how copper kills bacteria

New fossil discovery sheds light on the early evolution of animal nervous systems

A battle of rafts: How molecular dynamics in CAR T cells explain their cancer-killing behavior

Study shows how plant roots access deeper soils in search of water

Study reveals cost differences between Medicare Advantage and traditional Medicare patients in cancer drugs

‘What is that?’ UCalgary scientists explain white patch that appears near northern lights

How many children use Tik Tok against the rules? Most, study finds

Scientists find out why aphasia patients lose the ability to talk about the past and future

Tickling the nerves: Why crime content is popular

Intelligent fight: AI enhances cervical cancer detection

Breakthrough study reveals the secrets behind cordierite’s anomalous thermal expansion

Patient-reported influence of sociopolitical issues on post-Dobbs vasectomy decisions

Radon exposure and gestational diabetes

EMBARGOED UNTIL 1600 GMT, FRIDAY 10 JANUARY 2025: Northumbria space physicist honoured by Royal Astronomical Society

Medicare rules may reduce prescription steering

Red light linked to lowered risk of blood clots

Menarini Group and Insilico Medicine enter a second exclusive global license agreement for an AI discovered preclinical asset targeting high unmet needs in oncology

Climate fee on food could effectively cut greenhouse gas emissions in agriculture while ensuring a social balance

Harnessing microwave flow reaction to convert biomass into useful sugars

[Press-News.org] New evidence reveals tamoxifen reduces breast cancer rates by nearly a third for 20 years